|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Medicine and Dentistry New Jersey |
|---|---|
| Collaborator: |
National Institute of Neurological Disorders and Stroke (NINDS) |
| Information provided by: | University of Medicine and Dentistry New Jersey |
| ClinicalTrials.gov Identifier: | NCT00004732 |
Purpose
The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).
| Condition | Intervention | Phase |
|---|---|---|
|
Atherosclerosis Stroke Carotid Stenosis Cerebral Infarction Myocardial Infarction |
Procedure: Carotid Endarterectomy (CEA) Procedure: Carotid Artery Stenting (CAS) |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) |
| Enrollment: | 2502 |
| Study Start Date: | December 2000 |
| Estimated Study Completion Date: | December 2016 |
| Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Carotid Artery Endarterectomy (CEA) |
Procedure: Carotid Endarterectomy (CEA)
CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
|
| Active Comparator: Carotid Artery Stenting (CAS) |
Procedure: Carotid Artery Stenting (CAS)
CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
Other Name: Angioplasty of carotid artery and stent placement.
|
The primary aim of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to contrast the relative effectiveness of carotid artery stenting (CAS) versus carotid endarterectomy (CEA) in preventing stroke, myocardial infarction, and death. Stents are medical devices approved and commonly used for treatment of heart disease. The stent that will be used in this trial is the RX ACCULINK(TM) Carotid Stent System, an elastic-like metal scaffold that is expanded inside a carotid artery to hold the vessel open.
The RX ACCUNET(TM) Embolic Protection System (an umbrella-like device that expands above the narrowed portion of the carotid artery) will be used in conjunction with the RX ACCULINK stent. The RX ACCUNET system is designed to capture embolic material that could break off from the narrowed area in the carotid artery while still allowing blood to flow through the vessel during the procedure. Embolic material could block blood flow to the arteries beyond the narrowing and be harmful to the brain. The RX ACCUNET System is closed and removed after the stent is placed.
CEA involves a neck incision and physical removal of the plaque from the inside of the artery. CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. The stent is then placed to cover the plaque and hold the artery open. Participants will be randomly assigned to undergo either CAS or CEA, and all patients will receive best medical management, which includes treatment with aspirin, treatment of high blood pressure, and treatment of other stroke risk factors. Participants will be followed for up to ten years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Show 116 Study Locations| Principal Investigator: | Thomas G. Brott, M.D. | Mayo Clinic and University of Medicine and Dentistry New Jersey |
More Information
| Responsible Party: | Thomas G. Brott, MD, Principal Investigator, Mayo Clinic and University of Medicine and Dentistry New Jersey |
| ClinicalTrials.gov Identifier: | NCT00004732 History of Changes |
| Other Study ID Numbers: | 0119970017, R01NS038384 |
| Study First Received: | February 25, 2000 |
| Last Updated: | August 2, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
angioplasty asymptomatic atherosclerosis carotid endarterectomy carotid stenting CREST Cerebral Infarction device intervention |
restenosis revascularization stenosis stent stroke symptomatic surgery transient ischemic attack |
|
Atherosclerosis Carotid Stenosis Cerebral Infarction Stroke Constriction, Pathologic Infarction Myocardial Infarction Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Carotid Artery Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Brain Infarction Brain Ischemia Pathological Conditions, Anatomical Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases |